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Increasing number of elderly people and changed age 
structure led to an evaluation of the number of elderly 
people who suffer from cognitive function disorders and 
dementia — a severe cognitive disorder that develops 
gradually and is accompanied by a decrease in cognitive 
activity of the brain, loss of previously acquired know-
ledge, the ability to take care of themselves and be re-
sponsible for their actions.
According to the World Health Organization 
(WHO), there are almost 50 million dementia patients 
in the world, about 10 million new cases are registered 
annually, with two-thirds of them being patients with Al-
zheimer’s disease (AD). This is an extremely important 
medical and social problem due to the need for constant 
physical, psychological care for patients and significant 
economic costs. Prognosing is rather disappointing: by 
2030, the number of patients expected to increase to 
82 million, and by 2050 — up to 152 million [1]. High 
prevalence combined with enormous socio-economic 
significance makes dementia one of the priorities of the 
WHO activity.
Recently, there was convincing evidence that diabe-
tes mellitus (DM), primarily type 2, is an independent 
factor for the development of cognitive impairment and 
is associated with an increased risk for dementia deve-
lopment, the main causes of which are AD and vascular 
dementia [2].
The results of epidemiological, visualization and 
autopsy studies showed the presence of both cerebro-
vascular and neurodegenerative mechanisms of brain 
lesions in the central nervous system. According to a 
number of large-scale prospective studies, the risk of 
dementia in patients with DM type 2 increases almost 
twice, with the risk of vascular dementia increasing by 
2–2.5 times, and Alzheimer’s disease — approximate-
ly 1.5 times [3, 4]. Recently, it is noted that DM type 2 
is characterized by the development of mixed type de-
mentia — vascular and Alzheimer’s [5]. In addition, 
it has been found that type 2 DM can also affect the 
prevalence of moderate cognitive impairment, which 
is considered to be preclinical dementia. It is predicted 
that the increase in the number of patients with type 2 
DM and aging will contribute to a further increase in 
these indicators [6].
In turn, the cognitive disorders in the DM impedes 
the patient’s adaptation, adversely affects compliance, 
worsens the performance of medical recommendations, 
in particular regarding diet, oral hypoglycemic agents, 
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insulin therapy, self-monitoring, etc., which makes it 
impossible to compensate for the disease and poses a se-
rious threat to the occurrence of episodes of hypoglyce-
mia and fatal consequences.
Recently, special attention of scientists is given to the 
connection between the DM and AD, which, as it turned 
out, have common mechanisms for the emergence and 
interconnection.
AD is the most common form of primary degenera-
tive dementia of the late age, characterized by gradual 
low-grade onset, a steady progression of memory di-
sorders and higher cortical functions up to the total col-
lapse of intelligence and mental activity in general, as 
well as a characteristic complex of neuropathological 
symptoms. For the first time, the disease was described 
in 1907 by the German psychiatrist Alois Alzheimer. As 
a rule, it is found in people older than 65 years, but there 
is an early AD — a rare form of the disease. Dementia 
at AD with an early onset is characterized by a debut at 
the age of 65 years, with a more rapid course and the 
prevalence of aphasia-apraxia-agnosia symptoms. Ear-
ly onset is more often associated with a family history 
of the disease. If a person suffers from this form of AD, 
the risk of getting sick in his children is about 50 %. De-
mentia at AD with a late onset runs more slowly, with 
predominant memory impairment. The disease occurs 
sporadically [7, 8].
AD frequency increases with age. So, at the age 
of 65–69 years, it is 3 %, 70–74 years — 6 %, 75–79 
years — 9 %, 80–84 years — 23 %, 85–89 years — 40 %, 
over 90 years — 69 % [9].
The mechanisms that underlie cognitive dysfunction 
in type 2 DM have not been fully disclosed at the same 
time, but a number of convincing hypotheses regarding 
the formation of vascular, neurodegenerative and meta-
bolic disorders have been proposed.
The factors for the development of cognitive impair-
ment in DM include hyperthyroidism and hypoglyce-
mia, hyperinsulinemia, cerebral insulin resistance, the 
formation of end-product glycation, the competition of 
insulin-degrading enzyme with inhibition of the deg-
radation of β-amyloid peptides, micro- and macrovas-
cular cerebral violations, inflammation, acute cerebro-
vascular abnormalities of blood circulation, etc. In the 
end, it is likely that the cause is multifactorial, but the 
leading role belongs to chronic hyperglycemia and in-
sulin resistance [6].
Previously it was believed that glucose is consumed by 
the brain due to insulin, independently due to GLUT-1 
and GLUT-3 transporters, and insulin signaling mecha-
nisms are implemented mainly on the periphery. At the 
same time, it is finally discovered that this hormone has 
a neuromodulatory effect on the brain. Signaling of insu-
lin is involved in numerous cerebral functions, including 
cognition and memory. It is proved that insulin directly 
provides glucose metabolism in the structures of the cen-
tral nervous system [10].
In the brain, insulin and insulin-like growth factor 
(IGF) rapidly bind to tyrosine kinase receptors, IGF 
receptors and insulin receptors due to the high degree of 
identity. Insulin receptors are localized in certain parts 
of the brain, namely the olfactory bulb, the cerebral cor-
tex, the hypothalamus, the tonsil, and the striate body, 
but their highest concentration is in the hippocampus, 
which is responsible for the mnemonic functions. The 
binding of insulin to the receptor substrate leads to its 
autophosphorylation, which initiates the activation of 
phosphatidylinositide-3-kinase, which stimulates the 
production of protein kinase B and inhibition of gly-
cogen synthase-3 kinase. All this ensures membrane-
stabilizing action by suppressing the production of free 
radicals. It is proved that insulin-stimulated glucose 
transport in neurons increases the activity of cholinergic 
synapses in the central nervous system, which creates a 
substrate for the implementation of higher brain func-
tions. In turn, experimental DM in animals contributes 
to the reduction of neuroplasticity in the neurons of the 
hippocampus in the context of a violation of glutamate 
neurotransmission due to a decrease in the density of 
NMDA receptors [10–12].
Today, there is no doubt that one of the leading fac-
tors for the development of cognitive impairment in 
diabetes is chronic hyperglycemia, which manifestation 
is associated with cognitive deficits. The results of many 
studies in patients with DM of both types have de-
monstrated a close relationship between glycemia and 
glycated hemoglobin (HbA1c) and disorders of higher 
brain function. It has also been established that a higher 
average daily glycemia is associated with an increased 
risk of dementia. Negative correlation with cognitive 
functions also was revealed for the index of postpran-
dial glycemia [13].
As a result of persistent hyperglycemia, processes 
of glucose binding to amino groups of proteins are en-
hanced, with the formation of heterogeneous and un-
stable compounds — end-product glycation, which have 
the ability to modify neurofibrillary tau protein tangles 
and beta-amyloid plaques, which obviously contributes 
to the progression of neurodegeneration in AD.
Therefore, according to the scientists’ results, the 
better control of blood glucose levels is necessary to pre-
vent the development of cognitive impairments of diffe-
rent origin in patients with type 2 DM [13].
On the other hand, an extremely important factor in 
the development and progression of cognitive disorders 
is hypoglycemia, because normal brain function de-
pends directly on the level of glucose as the main source 
of energy for cerebral metabolism. Acute hypoglycemia, 
in addition to neuroglycopenic reactions, provokes car-
diovascular crises and hemorheological disorders along 
with the activation of the sympathoadrenal system and 
hormonal dysregulation. At the same time, hemody-
namic and hemorheological disorders that develop in the 
context of endothelial dysfunction, oxidative stress, vio-
lation of the cytokine link of immune regulation, activa-
tion of apoptosis factors, etc., increase the risk of local 
focal tissue ischemia and the manifestation of vascular 
events [14].
According to the experimental studies, hypoglyce-
mia leads to necrosis of neurons in the hippocampus and 
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cortical regions, and repeated hypoglycemia can lead to 
synaptic dysfunction, even in the absence of neurons’ 
death [15].
At the same time, the results of studies demonstra-
ted that the relationship between the risk for developing 
cognitive impairment and the frequency and severity of 
hypoglycemic episodes are controversial. According to 
some data, in patients with single or multiple episodes 
of hypoglycemia, a proportional increase in the risk of 
dementia was observed [16]. Another Edinburgh Type 2 
Diabetes Study has shown that both history of hypogly-
cemia and an incident of hypoglycemia are associated 
with severe cognitive disorder [17].
In turn, the disruption of cognitive function in-
creases the risk of hypoglycemia due to poor patient 
compliance, dietary disorders, the overdose of hypo-
glycemic agents, and so on. Thus, in the ADVANCE 
study, severe cognitive disorder, established on the basis 
of MMSE test, contributed to a significant (more than 
double) increase in the risk of hypoglycemia [18]. It is 
noted that the presence of cognitive impairments pre-
vents the timely recognition of patient hypoglycemia, 
the possibility of timely and adequate medical care, 
poses a threat to the occurrence of severe hypoglycemic 
episodes and various complications that threaten fatal 
consequences [16–18].
In patients with type 2 DM, a negative correlation 
between cognitive function and insulin, C-peptide and 
HOMA index is also established, indicating the role of 
insulin resistance and hyperinsulinemia in the develop-
ment of cerebral disorders in this disease [19].
Studies in recent years show that cognitive dysfunc-
tion with type 2 DM on the background of AD can be 
related to insulin resistance of the brain, which leads to 
neurodegeneration, that allowed scientists to conven-
tionally consider dementia a kind of “diabetes of the 
brain” or “type 3 diabetes” [20].
This hypothesis is confirmed by the fact that the le-
vel of insulin and the number of insulin receptors in AD 
patients, especially in the brain, related to learning and 
memory, are significantly higher than in healthy sub-
jects. As already noted, insulin and its signaling path-
ways not only regulate the metabolism of glucose and 
energy but also modulate learning and memory. Since 
cognitive structures such as the hippocampus and the 
anterior cortex (part of the cerebral cortex located in 
the temporal lobe related to the hippocampal forma-
tion) have a high density of insulin receptors and can 
locally produce insulin, an obstacle in any way insulin 
signaling can lead to cognitive impairments, most of 
which is associated with memory, attention, and execu-
tive functions [21].
This is confirmed by the fact that there is a decrease 
in the expression of genes encoding insulin secretion sig-
naling proteins and a lower level of several proteins in 
this pathway at the intersection of Alzheimer’s disease. 
In addition, plaques that occur in AD and neurofibrillary 
tangles contain glycated protein, the formation of which 
may be provoked by the impossibility of insulin action 
[21–23].
Experimental studies have shown that due to insu-
lin resistance excessive proteins activation of the signa-
ling pathway of insulin in the brain causes the forma-
tion of amyloid plaques, which negatively affects both 
short-term and long-term memory, as well as cognitive 
function. In this case, there is a violation of the cascade 
reactions signaling, including inhibition of phosphati-
dylinositide-3-kinase, protein kinase B and activation of 
3-kinase glycogen synthase, which induces hyperphos-
phorylation of tau protein, accumulation of oligomers 
and oxidative stress leading to mitochondrial dysfunc-
tion, apoptosis, secretion of proinflammatory cytokines, 
and neurodegeneration [22, 23].
In particular, it has been proven that insulin is in-
volved in the regulation of protein synthesis of the precur-
sor of amyloid APP and β-amyloid, the main component 
of amyloid deposits, and also regulates the phosphory-
lation of tau protein, which forms the basis of neurofi-
brillary formations. In this case, this hormone stimulates 
the transferring of APP-β-amyloid to the membrane and 
extracellular release of β-amyloid, and insulin resistance 
causes an increase in the activity of β- and γ-secretase, 
with subsequent increase in the content of β-amyloid 
[24, 25].
Another theory is related to the reduction in the 
elimination of β-amyloid, whose cerebral clearance 
can be implemented by microglial capture or by the 
insulin-degrading enzyme. However, insulin resistance 
competes with β-amyloid, which contributes to the ac-
cumulation of β-amyloid in the brain [29, 30]. Lowe-
ring insulin sensitivity may result in the activation of the 
enzyme GSK-3beta, which catalyzes the phosphoryla-
tion of tau protein, a major component of neurofibril-
lary tangles [26].
In recent years, the hypothesis about the role of hy-
peramylinemia in the development of AD has been ac-
tively discussed. Amylin (or islet amyloid polypeptide) 
is a neuroendocrine hormone secreted by beta cells to-
gether with insulin. By interacting with the nuclei of the 
brain, it regulates the sense of saturation through cen-
tral mechanisms, reduces appetite, stomach  emptying 
speed, and also suppresses glucagon secretion, preven-
ting postprandial hyperglycemia. Today amylin is con-
sidered as the third islet pancreatic hormone (along 
with insulin and glucagon), which is involved in main-
taining glucose homeostasis. In this case, hyperamy-
linemia, which is often recorded in patients with obesity 
and insulin resistance, leads to oligomerization of this 
polypeptide, an increase in its deposition in pancreatic 
islets, a decrease in the number of β-cells by amplifying 
the processes of apoptosis and/or necrosis and thereby 
increasing the rate of absolute insulin deficiency de-
velopment. A recent study has shown that polymor-
phism of the amylin gene is associated with AD [27]. 
Independent studies have shown that elderly patients 
with AD or moderate cognitive impairment had lower 
amylin plasma concentrations than controls [28]. The 
brain tissue analysis of persons with AD, which runs 
on the background of DM, revealed the deposition of a 
significant amount of amylin in the gray matter and in 
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the walls of the brain vessels. It is noteworthy that this 
substance was found in the brain of patients with AD 
without diabetes [29]. In view of the above, an amylin 
analogue used as an informative and non-invasive chal-
lenge test for Alzheimer’s disease [30].
Thus, hyperglycemia, activating free radical oxida-
tion and non-enzymatic glycosylation of proteins, the 
polyol glucose metabolism pathway, the formation of 
end-product glycation, leads to endothelial dysfunction, 
hemorheological disorders with the development of mi-
crovascular lesions of the brain; and the presence of insu-
lin resistance and hyperinsulinemia further contribute to 
the development and progression of neurodegeneration 
mechanisms, as well as dyslipidemia, arterial hyperten-
sion and cerebral atherosclerosis, which generally causes 
the development of cerebral lesions. Due to the prevai-
ling cardiovascular, neurodegenerative and metabolic 
disorders, there is a gradual decrease in the gray matter of 
the brain, changes in its microstructure and white matter 
atrophy.
The results of studies have shown that in patients 
with type 2 DM the degree of cognitive impairment is 
associated not only with carbohydrate dysmetabolism 
but also with the presence of arterial hypertension, 
dyslipidemia, and acute cerebrovascular accidents. At 
the same time, the risk of cognitive impairment per-
sists even in case of correction of a number of its fac-
tors, such as arterial hypertension and dyslipidemia, 
which may be indicative of the determining role of 
carbohydrate metabolism disorders (chronic hyper-
glycemia, insulin resistance, hyperinsulinemia, and 
hypoglycemia) in the development of diabetic cerebral 
disorders [25, 31].
Since chronic hyperglycemia plays a leading role in 
the development of cerebral diabetic disorders, the key 
to preventing the development and progression of cog-
nitive impairment in diabetes is satisfactory glycemic 
control. At the same time, the advantages of maximum 
compensation for type 2 DM are controversial. Thus, in 
a number of studies, satisfactory glycemic control was 
associated with less pronounced cognitive impairment 
[32, 33]. In contrast, the ACCORD-MIND study, con-
ducted in 52 clinical centres in North America with the 
involvement of about 3,000 patients with type 2 DM, has 
shown that active glycemic control is not associated with 
improved cognitive performance in patients with type 2 
DM [34]. In addition, such approach may be dangerous 
in terms of the risk of hypoglycemic reaction, which ad-
versely affects cognitive function [17, 18].
Taking into account all of the foregoing, the strategy 
for the treatment and prevention of cognitive impair-
ment in diabetes should be individualized in such a way 
as to minimize the occurrence of both hyperglycemia 
and hypoglycemia and to be effective in the aspect of the 
prevention of vascular complications [35].
Currently, only a few groups of drugs are prescribed 
for the treatment of AD, while their effects are rather 
modest and pathogenetically do not impact the under-
lying process of the disease. Due to the close pathogene-
tic linkages of the diabetes mellitus development mecha-
nisms and AD, today the issue of the antidiabetic therapy 
influence on the cognitive function of patients with DM 
is actively studied.
In some studies, both monotherapy with insulin drugs 
and in combination with oral hypoglycemic agents posi-
tively influence the cognitive functions in AD, which, 
according to the authors’ data, is related to the optimiza-
tion of glycemic control [36]. Individual works showed 
improvement in memory and other cognitive functions 
against the background of the intranasal insulin use in 
AD [37].
At the same time, several other studies have found 
that the use of insulin drugs, especially in the elderly 
people, is more often associated with deterioration of 
cognitive function, which is associated with an increased 
risk of hypoglycemia and low compliance of patients. In 
particular, in Rotterdam study, the patients received in-
sulin drugs had the highest risk for dementia [4].
Therefore, during the treatment of elderly persons 
with cognitive impairment, it is necessary to avoid the 
administration of short- and short-acting insulin drugs, 
complex administration regimens and, as a baseline the-
rapy, to favor low-profile insulin hypoglycemic reac-
tions, in particular, insulin analogues.
As the results of many studies provided convincing 
evidence of the role of insulin resistance in the develop-
ment of cognitive impairment in type 2 DM, the most 
promising hypoglycemic agents to prevent their deve-
lopment are recognized drugs from the group of insulin 
sensitizers.
To date, the first choice for the treatment of type 2 
DM is metformin [38], which has unique pleiotropic 
effects that affect the main pathogenetic links in the 
development of cerebral diabetic lesions: chronic hy-
perglycemia, insulin resistance, hyperinsulinemia, hy-
perlipidemia, inflammation of the vascular walls and 
endothelial dysfunction, oxidative stress, disturbances 
of the rheological properties of blood, prevents the deve-
lopment of GTPM and has a high safety spectrum related 
to the occurrence of hypoglycemic reactions.
The results of recent studies have shown that, besides 
the listed mechanisms, metformin possesses a whole 
spectrum of neurospecific properties that generally pre-
vent the progression of diabetic cerebral abnormalities 
and provide a nootropic effect. First of all, the neuro-
protective activity of metformin is indicated, which is 
ensured by activation of AMPK-dependent pathways 
in human nervous stem cells, which causes angioge-
nesis, neurogenesis, and induction of autophagy [38]. 
It is proved that the increase in neurotrophic factors 
in the brain is observed against the background of the 
drug application, and the intensity of neurogenesis in 
the hippocampus increases twice [39, 40]. The results 
of experimental studies have shown that metformin re-
duces neurocytes apoptosis [41]. There is also evidence 
that the use of metformin prevents the brain mitochon-
drial dysfunction [42]. The studies of recent years have 
shown that this drug effectively inhibits the formation 
of beta-amyloid and prevents the development and pro-
gression of AD. It has been shown that the metformin 
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use background revealed a significant deterioration in 
the expression and β-secretase activity, leading to the 
formation of Aβ (β-amyloid) [43, 44]. Metformin abili-
ty to reduce the activity of acetylcholinesterase deserves 
particular attention.
According to clinical observations, metformin is as-
sociated with a decrease in the dementia frequency and 
cognitive function improvement in elderly patients with 
DM. In a large-scale study conducted in the United 
States, the use of metformin in the elderly suffering from 
diabetes (up to 6,000 patients included in the analysis), 
the risk of development of neurodegenerative diseases, 
including AD, did not undergo statistically significant 
changes 1 year after the onset, the difference in 2 years 
decreased by 29 %, in the period from 2 to 4 years — by 
41 %, and when applied more than 4 years — by 84 % 
compared with non-recipients [46].
It is noteworthy that the established effectiveness of 
metformin use at AD in people without diabetes, which 
turned out to be safe, was associated with improvement 
in executive functions, in learning, memory, and atten-
tion [47].
However, in some studies, with the use of metformin, 
an increase in the incidence of cognitive impairment was 
observed in patients with vitamin B12 deficiency [48, 49]. 
The administration of a prolonged form of the drug en-
sures minimizing the risk of developing vitamin B12 defi-
ciency against the background of metformin use due to 
its absorption throughout the intestine without blocking 
the vitamin B12 receptors in the ileum [50].
Hopes on the promising use of thiazolidinediones to 
treat and prevent cognitive impairment have not found 
convincing clinical evidence. In a number of studies, 
even deterioration of cognitive function was observed on 
the background of thiazolidinediones use. In particular, 
in the ACCORD-MIND cohort, the effect of rosigli-
tazone was associated with a greater reduction in cogni-
tive performance than insulin therapy [51]. According to 
another large-scale study, the risk of dementia increased 
by more than 5-fold in patients receiving thiazolidine-
diones compared to those receiving metformin [52].
The results of the most studies indicate a negative 
effect of sulfonylureas on cognitive function, which is 
associated with a higher incidence of hypoglycemic re-
sponses in the context of receiving these drugs.
It has been found that the risk of severe hypoglycemia 
in the elderly who receive the drugs of this group, in par-
ticular glibenclamide, is significantly higher than that of 
young adults, as sensitivity to them may increase, espe-
cially in individuals over the age of 80, which exacerbates 
cognitive impairment [53].
During another retrospective cohort study, it was 
found that in rigidly controlled (HbA1c < 7 %) patients 
with type 2 DM and dementia aged ≥ 65 years, the vast 
majority of whom received sulfonylureas and/or insulin, 
there was a much higher risk of hypoglycemia, which, 
according to researchers’ data, led to the progression of 
dementia. With this in mind, researchers point out the 
need to revise therapy with the patients transfer to other 
hypoglycemic agents [54].
Recently, there were papers devoted to the study of 
the efficiency of incretin modulators in preserving cogni-
tive functions.
According to experimental studies data, glucagon-
like peptide-1 (GLP-1) and its analogues crossing the 
blood-brain barrier exhibit the ability to mediate many 
neuronal functions by improving neurogenesis, redu-
cing apoptosis, protecting neurons from oxidative stress, 
and reducing the formation of amyloid plaques, which 
has a positive effect on cognitive functions [57–60]. It 
was shown that GLP-1 agonists decrease the level of 
α-amyloid oligomers and toxicity in cultured primary 
neurons and neuronal cell lines [56, 57]. However,  other 
works do not record the impact of GLP-1 analogues 
long-term use on amyloid plaques [58].
Similar effects were also observed for inhibitors of di-
peptidyl peptidase-4. In experimental animal studies, the 
drugs of this group revealed neuroprotective properties 
in both AD and in vascular dementia due to the amyloid 
plaques formation reduction, activation of neurogenesis, 
antiapoptotic and antioxidant properties [59, 60].
Also, the effect of SGLT2 inhibitors on cognitive 
function is studied today. It has been shown that the use 
of SGLT2 inhibitor empagliflozin in experimental DM 
type 2 in mice resulted in a decrease in the manifesta-
tions of cognitive dysfunction caused by additional ir-
radiation of the brain, which, according to the authors’ 
data, is associated with positive cardiovascular effects 
of the drug [61]. It has also been found that SGLT2 in-
hibitors, in particular, dapagliflozin and canagliflozin, 
have anticholinesterase activity in experimental ani-
mals and therefore potentially improve cognitive func-
tion [62, 63].
One of the most promising antidiabetic agents that 
can be effective in the treatment and prophylaxis of AD 
in diabetes are amylinomimetics, in particular, pram-
lintide — a synthetic analogue of amylin. Recent stu-
dies have shown that the use of amylin and pramlintide 
positively affects the main pathological components of 
AD, in particular, amyloid plaques, tauopathy, neuroin-
flammation and other cerebral mechanisms, which were 
accompanied by improvements in training and memory 
rates in experimental models. Today amylinomimetics 
are considered as the only new therapeutic agents for tar-
geting multiple indices of neurodegeneration in the brain 
in AD [30, 64, 65].
Today, the question of the effectiveness of incretin 
modulators, SGLT2 inhibitors, and amylinomime tics 
needs further study in experimental and clinical re-
searches.
Thus, the results of numerous studies indicate an in-
crease in the rate of development of AD in diabetes, the 
existence of close mechanisms of development and the 
inner convergence of these diseases, indicating the need 
to find new diagnostic methods and common pathoge-
netic treatment.
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Цукровий діабет і хвороба 
Альцгеймера
Резюме. В оглядовій статті наведені сучасні відомості 
щодо епідеміології та чинників ризику розвитку хворо-
би Альцгеймера при цукровому діабеті. Проаналізовано 
дані літератури щодо основних патогенетичних ланок 
розвитку нейродегенеративних порушень у пацієнтів із 
цукровим діабетом, а також механізмів взаємообтяжен-
ня. Наведені результати клінічних та експериментальних 
досліджень щодо можливостей патогенетичної корекції 
когнітивних порушень при хворобі Альцгеймера, яка 
перебігає на тлі цукрового діабету, зазначені найбільш 
перспективні напрямки наукових досліджень із цієї про-
блеми.
Ключові слова: цукровий діабет; хвороба Альцгеймера; 
когнітивні порушення; огляд
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Сахарный диабет и болезнь 
Альцгеймера
Резюме. В обзорной статье приведены современные све-
дения об эпидемиологии и факторах риска развития бо-
лезни Альцгеймера при сахарном диабете. Проанализиро-
ваны данные литературы по основным патогенетическим 
звеньям развития нейродегенеративных нарушений у па-
циентов с сахарным диабетом, а также механизмам взаи-
моотягощения. Представлены результаты клинических и 
экспериментальных исследований относительно возмож-
ностей патогенетической коррекции когнитивных нару-
шений при болезни Альцгеймера, которая протекает на 
фоне сахарного диабета, указаны наиболее перспективные 
направления научных исследований по данной проблеме.
Ключевые слова: сахарный диабет; болезнь Альцгейме-
ра; когнитивные нарушения; обзор
